Citigroup Issues Positive Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its target price increased by analysts at Citigroup from $113.00 to $210.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “sell” rating on the life sciences company’s stock. Citigroup‘s price target would suggest a potential downside of 8.06% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Royal Bank Of Canada lifted their target price on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Stifel Nicolaus boosted their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler raised their price target on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $244.24.

Illumina Trading Down 3.2%

Shares of Illumina stock traded down $7.58 during trading hours on Monday, hitting $228.41. The company’s stock had a trading volume of 1,632,602 shares, compared to its average volume of 2,175,053. The stock has a market cap of $34.49 billion, a price-to-earnings ratio of 39.37, a P/E/G ratio of 3.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina has a twelve month low of $112.65 and a twelve month high of $309.35. The firm has a fifty day moving average of $249.30 and a 200-day moving average of $176.18.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company earned $1.34 EPS. Research analysts forecast that Illumina will post 5.43 EPS for the current year.

Insider Activity

In other news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 2,061,235 shares of company stock valued at $436,356,102. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the company. Baker Tilly Wealth Management LLC increased its holdings in Illumina by 3.3% in the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after buying an additional 42 shares during the last quarter. Ashton Thomas Securities LLC boosted its position in shares of Illumina by 3.3% during the 3rd quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after acquiring an additional 43 shares in the last quarter. Elevation Wealth Partners LLC increased its holdings in shares of Illumina by 19.7% in the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock valued at $80,000 after acquiring an additional 48 shares during the last quarter. Evergreen Capital Management LLC increased its holdings in shares of Illumina by 0.5% in the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock valued at $2,593,000 after acquiring an additional 50 shares during the last quarter. Finally, Pinnacle Associates Ltd. raised its position in shares of Illumina by 2.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock worth $686,000 after acquiring an additional 54 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported third-quarter adjusted earnings above expectations and raised its full-year revenue and earnings guidance. Healthy margins, solid free cash flow and continued clinical sequencing demand provided fundamental support. Illumina (ILMN) Stock Falls After Q3 Results Lift Guidance
• Positive Sentiment: Strong demand for clinical sequencing and robust placements of the NovaSeq X platform are supporting potential margin and earnings expansion. New offerings, including the BioInsight software suite, could add to future growth. The top 5 analyst questions from Illumina’s Q3 earnings call
• Positive Sentiment: Analyst coverage continues to highlight Illumina’s long-term growth potential, including the contribution of international revenue and the company’s exposure to expanding genomic-testing markets. Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: International revenue trends remain an important variable for Wall Street forecasts. Investors are assessing whether overseas growth can offset uneven demand across Illumina’s end markets. Don’t Overlook Illumina International Revenue Trends While Assessing the Stock
• Neutral Sentiment: A report projects the global forensic technologies and services market will grow substantially through 2030, potentially creating longer-term opportunities for companies involved in advanced DNA sequencing and AI-enabled forensics. Forensic Technologies and Services Global Strategic Business Report
• Negative Sentiment: The market reaction was negative because investors viewed Illumina’s valuation—near 40 times trailing earnings—as demanding, even after the guidance increase. The results suggested a more measured growth profile than the valuation may imply. What Sent Illumina Stock Lower?
• Negative Sentiment: Research and applied markets remain weak, partially offsetting clinical momentum. Analyst downgrades, a lower JPMorgan price expectation and the stock’s move below its 50-day moving average added further pressure. JPMorgan Lowered Expectations for Illumina Stock

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.